You are here:

aprepitant (Emend)

Advice

following an abbreviated submission

aprepitant (Emend®) is accepted for use within NHS Scotland.

Indication under review: As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).

SMC has previously accepted aprepitant for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy in adults. The marketing authorisation has since been extended to cover prevention of nausea and vomiting in adults associated with highly emetogenic non-cisplatin based chemotherapy.  SMC does not plan to assess this minor licence extension.

Drug Details

Drug Name: aprepitant (Emend)
SMC Drug ID: 1252/17
Manufacturer: MSD
Indication: As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 10 July 2017

Back